Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04482673 · ClinicalTrials.gov registry record · Phase 4
Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection
A Phase 4 study of COVID-19 and Vitamin D Deficiency, sponsored by Medical University of South Carolina.
- Active
- Registry status
- Phase 4
- Development phase
- 95
- Enrollment target
- 1
- Study location
NCT04482673: Active Phase 4 study of COVID-19 and Vitamin D Deficiency, sponsored by Medical University of South Carolina.
NCT04482673 is a Phase 4 study of COVID-19 and Vitamin D Deficiency that is active but no longer recruiting, run by Medical University of South Carolina. The registered enrollment target is 95 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04482673, a Phase 4 study of COVID-19 and Vitamin D Deficiency, is active but no longer recruiting, sponsored by Medical University of South Carolina.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 95 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate how useful vitamin D supplementation is in reducing the severity of COVID-19 symptoms and the body's inflammatory and infection-fighting response to COVID-19. Individuals ≥50 years of age and older who are tested for COVID-19 and negative will be randomized (like flipping a coin) to either daily high dose vitamin D supplementation (6000 IU vitamin D3/day) vs. standard of care. Those individuals ≥50 years of age or older who test positive for COVID-19 at baseline will be randomized to bolus vitamin D (20,000 IU/day for 3 days) followed by high dose (6000 IU vitamin D/day) vs. standard of care for 12 months. All participants will receive a multivitamin containing vitamin D.
Primary Outcome
metabolite of vitamin D
Conditions Studied
Interventions
- DRUG Daily Vitamin D3
- DRUG Daily placebo
- DRUG Bolus vitamin D3
- DRUG Bolus placebo
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2020-07-31 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 4 |
What the registry record for NCT04482673 still lists
NCT04482673 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 4 interventions - of which Daily Vitamin D3 is the first listed.
NCT04482673 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT04482673 about?
NCT04482673 is a clinical study titled "Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection". The purpose of this study is to evaluate how useful vitamin D supplementation is in reducing the severity of COVID-19 symptoms and the body's inflammatory and infection-fighting response to COVID-19. Individuals ≥50 years of age and older who are tested for COVID-19 and negative will be randomized (...
What is the current status of trial NCT04482673?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 95 participants. The study started on 2020-07-31. Estimated completion is 2023-12-31.
What conditions does trial NCT04482673 study?
This clinical trial studies the following conditions: COVID-19, Vitamin D Deficiency, Respiratory Viral Infection.
What interventions are being tested in trial NCT04482673?
The interventions under investigation include: Daily Vitamin D3 (DRUG), Daily placebo (DRUG), Bolus vitamin D3 (DRUG), Bolus placebo (DRUG).
Who is sponsoring clinical trial NCT04482673?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04482673 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04482673's enrollment target sits among peer trials
95 207th of 298 higher than 92 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
RECRUITING · Phase 4
-
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
RECRUITING · Phase 4
-
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
COVID-19 Reactogenicity
ACTIVE NOT RECRUITING · Phase 4
-
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI